Firefly Neuroscience Shares Exciting Update for Shareholders
Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF) is an innovative Artificial Intelligence (“AI”) technology company focused on creating advanced neuroscientific solutions to enhance brain health for individuals facing mental health challenges and neurological disorders. Today, Firefly announced that it will host a shareholder update call to keep stakeholders updated on the company's recent developments and strategic innovations.
Details of the Upcoming Event
The upcoming shareholder update call aims to provide the latest information from Firefly. Here are the specifics:
Key Information
Event: Firefly Neuroscience Shareholder Update
Date: To be announced
Time: 5:00 PM Eastern Time
About Firefly Neuroscience
Firefly is dedicated to revolutionizing traditional methods of treating mental health issues through state-of-the-art technology. The company’s FDA-510(k) cleared Brain Network Analytics (BNA) platform is set to transform diagnostic and treatment approaches for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD.
Investment and Development Efforts
Over the past fifteen years, Firefly has invested around $60 million into the development of its BNA platform. This significant investment has enabled the company to create a robust database of brain wave tests and secure essential patent protections necessary for delivering cutting-edge technology solutions in the field of brain health.
Commercial Launch of the BNA Platform
Firefly is actively working on the commercial launch of its BNA platform, aiming to establish partnerships with pharmaceutical companies focused on drug research and clinical trials. Furthermore, the platform is designed for medical practitioners seeking innovative tools and solutions to improve patient diagnostics.
Technical Overview of the BNA
The BNA operates as a software as a medical solution (SAMS). It leverages advanced artificial intelligence and machine learning techniques on Firefly’s proprietary database. This extensive database includes standardized, high-definition, longitudinal electroencephalograms (EEGs) from over 17,000 patients, covering twelve neurological and mental health disorders, along with insights from clinically normal patient groups.
Enhancing Clinical Insights
When used alongside an FDA-cleared EEG system, the BNA platform provides clinicians with in-depth insights into brain function and cognition. These insights greatly enhance clinicians’ abilities to accurately diagnose mental illnesses and cognitive disorders while identifying the most suitable therapies or medications to optimize patient outcomes.
Investor Contact Information
For inquiries regarding investments in Firefly Neuroscience or to learn more about their innovative solutions, stakeholders are encouraged to reach out to the company’s investor relations team:
Investor Contact
KCSA Strategic Communications
Valter Pinto or Jack Perkins
Phone: (212) 896-1254
Email: Firefly@KCSA.com
Media Inquiries
For media relations or additional insights about Firefly Neuroscience, please contact:
Media Contact
KCSA Strategic Communications
Raquel Cona, Vice President
Phone: (516) 779-2630
Email: Rcona@KCSA.com
Frequently Asked Questions
What is the purpose of the shareholder update call?
The call aims to provide shareholders with updates on Firefly Neuroscience’s advancements and corporate strategies regarding their innovative solutions.
What technologies does Firefly Neuroscience focus on?
Firefly focuses on developing artificial intelligence-driven solutions for improving brain health, particularly through its BNA platform.
How does the BNA platform benefit clinicians?
The BNA platform enhances clinicians’ abilities to diagnose mental health and cognitive disorders accurately and determine effective treatments.
Who can I contact for investor relations inquiries?
For investment inquiries, contact KCSA Strategic Communications at (212) 896-1254 or email Firefly@KCSA.com.
What disorders does the BNA platform address?
The BNA platform addresses a variety of conditions, including depression, ADHD, anxiety disorders, and other neurocognitive issues.